Affordable Access

Opioid receptors in the gastrointestinal tract

Regulatory Peptides
Publication Date
DOI: 10.1016/j.regpep.2009.03.012
  • Alvimopan
  • Methylnaltrexone
  • Naloxone
  • Opioid Peptides
  • Enteric Nervous System
  • Opioid-Induced Bowel Dysfunction
  • Constipation
  • Peripherally Restricted Opioid Receptor Antagonists
  • Prokinetic Effects
  • Medicine


Abstract Opium is arguably one of the oldest herbal medicines, being used as analgesic, sedative and antidiarrheal drug for thousands of years. These effects mirror the actions of the endogenous opioid system and are mediated by the principal μ-, κ- and δ-opioid receptors. In the gut, met-enkephalin, leu-enkephalin, β-endorphin and dynorphin occur in both neurons and endocrine cells. When released, opioid peptides activate opioid receptors on the enteric circuitry controlling motility and secretion. As a result, inhibition of gastric emptying, increase in sphincter tone, induction of stationary motor patterns and blockade of peristalsis ensue. Together with inhibition of ion and fluid secretion, these effects cause constipation, one of the most frequent and troublesome adverse reactions of opioid analgesic therapy. Although laxatives are most frequently used to ameliorate opioid-induced bowel dysfunction, their efficacy is unsatisfactory. Specific antagonism of peripheral opioid receptors is a more rational approach. This goal is addressed by the use of opioid receptor antagonists with limited absorption such as oral prolonged-release naloxone and opioid receptor antagonists that do not penetrate the blood-brain barrier such as methylnaltrexone and alvimopan. Preliminary evidence indicates that peripherally restricted opioid receptor antagonists may act as prokinetic drugs in their own right.

There are no comments yet on this publication. Be the first to share your thoughts.